Summary: SNX-III (NEUREX Corporation, Menlo Park, CA, U.S.A.) an w-conopeptide, was tested for cy toprotection following normothermic ischemia using both a four-vessel occlusion model of severe forebrain isch emia and a model of transient middle cerebral artery oc clusion focal ischemia. Adult male Wi star rats were sub jected to 10 min of forebrain ischemia followed by 7 days of reperfusion. A single dose of SNX-Ill (5 mg/kg) was injected intravenously following delays of either 6 or 24 h after reperfusion. For I I rats treated with saline, there was 78 ± 13% CAl neuronal injury (mean ± SD); for I I given SNX-lli delayed by 6 h, injury was reduced to 35 ± 30% (p < 0.01); and remarkably; treatment delayed by 24 h (n = 10), still resulted in protection, with only 50 ±